CVS Health Corporation $CVS Shares Sold by Empowered Funds LLC

Empowered Funds LLC decreased its position in CVS Health Corporation (NYSE:CVS) by 9.1% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 120,742 shares of the pharmacy operator’s stock after selling 12,034 shares during the quarter. Empowered Funds LLC’s holdings in CVS Health were worth $12,491,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the company. Elevation Wealth Partners LLC boosted its position in CVS Health by 41.8% during the second quarter. Elevation Wealth Partners LLC now owns 356 shares of the pharmacy operator’s stock worth $37,000 after acquiring an additional 105 shares during the last quarter. Apella Capital LLC boosted its holdings in shares of CVS Health by 1.7% during the second quarter. Apella Capital LLC now owns 6,940 shares of the pharmacy operator’s stock worth $724,000 after purchasing an additional 117 shares during the last quarter. CYBER HORNET ETFs LLC grew its position in shares of CVS Health by 4.1% in the third quarter. CYBER HORNET ETFs LLC now owns 3,442 shares of the pharmacy operator’s stock valued at $259,000 after purchasing an additional 134 shares during the period. Northwestern Mutual Investment Management Company LLC increased its stake in CVS Health by 0.3% in the fourth quarter. Northwestern Mutual Investment Management Company LLC now owns 40,560 shares of the pharmacy operator’s stock valued at $3,219,000 after purchasing an additional 136 shares during the last quarter. Finally, CoreCap Advisors LLC lifted its position in CVS Health by 4.2% during the second quarter. CoreCap Advisors LLC now owns 3,481 shares of the pharmacy operator’s stock worth $360,000 after buying an additional 139 shares during the period. 80.66% of the stock is owned by institutional investors and hedge funds.

CVS Health Stock Up 0.2%

Shares of NYSE:CVS opened at $93.15 on Friday. The stock has a 50-day simple moving average of $101.42 and a 200-day simple moving average of $89.46. The stock has a market capitalization of $119.14 billion, a P/E ratio of 24.64, a PEG ratio of 0.91 and a beta of 0.61. CVS Health Corporation has a 1 year low of $69.51 and a 1 year high of $110.68. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.66 and a current ratio of 0.87.

CVS Health (NYSE:CVS) last announced its quarterly earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $1.87 by $0.71. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. The firm had revenue of $106.10 billion for the quarter, compared to analysts’ expectations of $100.03 billion. During the same period in the previous year, the company posted $1.81 earnings per share. CVS Health’s revenue was up 7.3% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. Equities analysts forecast that CVS Health Corporation will post 8.02 earnings per share for the current year.

CVS Health Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 23rd were issued a $0.665 dividend. This represents a $2.66 annualized dividend and a yield of 2.9%. The ex-dividend date was Thursday, July 23rd. CVS Health’s dividend payout ratio is currently 70.37%.

Wall Street Analyst Weigh In

Several research firms have commented on CVS. JPMorgan Chase & Co. lifted their price target on CVS Health from $111.00 to $118.00 and gave the company an “overweight” rating in a report on Wednesday, August 12th. Robert W. Baird set a $107.00 target price on shares of CVS Health in a research report on Thursday, August 6th. Sanford C. Bernstein boosted their target price on shares of CVS Health from $94.00 to $106.00 and gave the company an “outperform” rating in a report on Tuesday, May 12th. DA Davidson increased their price target on shares of CVS Health from $80.00 to $100.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Finally, Royal Bank Of Canada lifted their price target on shares of CVS Health from $107.00 to $113.00 and gave the company an “outperform” rating in a report on Thursday, July 9th. Twenty-two research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, CVS Health has a consensus rating of “Moderate Buy” and an average price target of $107.17.

More CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Pharmacy momentum supports the turnaround case. Rising prescription volumes, gains associated with Rite Aid and improving pharmacy profitability could provide support for CVS’s second-half outlook. This adds to the company’s recent earnings momentum, including revenue growth and an earnings beat in its latest reported quarter. How CVS’ Pharmacy and Consumer Wellness Is Positioned for H2 2026
• Positive Sentiment: Updated flu vaccines are now available nationwide. CVS Pharmacy and MinuteClinic are offering the 2026–2027 vaccines, while expanded testing and treatment services may increase seasonal customer traffic. A company survey found that more than 60% of consumers are likely to get a flu shot, though the earnings effect is likely to be seasonal and modest. CVS Pharmacy and MinuteClinic Now Offering Updated Flu Vaccines Nationwide
• Positive Sentiment: Value-focused coverage is reinforcing rebound expectations. Zacks characterizes CVS as a potential long-term value stock, while Trefis notes that the company’s historical drawdowns have often eventually recovered. These are sentiment and valuation arguments rather than new financial guidance, but they may attract investors seeking a healthcare turnaround at a relatively reasonable valuation. Why CVS Health Is a Top Value Stock for the Long-Term
• Neutral Sentiment: ACA insurer exits create both opportunity and uncertainty. Cigna, Molina and other carriers are leaving Obamacare exchanges in 2027. The disruption could create enrollment opportunities for Aetna, CVS’s insurance business, but also highlights regulatory, pricing and membership risks across the sector. All the Insurers Exiting ACA Obamacare Exchanges for 2027
• Negative Sentiment: Political pressure on vertically integrated healthcare companies remains a risk. Mark Cuban’s support for breaking up “big medicine” adds to scrutiny of insurers, pharmacy benefit managers and large healthcare platforms. No specific policy action against CVS was announced, but potential structural or regulatory changes could weigh on sentiment. Mark Cuban Backs Plan to Break Up Big Medicine

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.